|
|
|
|
| - Return to the Previous Page - |
| Lead drug candidate entered into Phase II trial in Multiple Sclerosis (MS) | Record Date: 9/2/2010
Company: Antisense Therapeutics |
February 02, 2005-In December 2004, the company initiated a Phase IIa clinical trial of its lead drug candidate ATL1102 in patients with MS. This follows the successful Phase I trial completed in 2004.
This Phase IIa trial has been designed to obtain preliminary evidence of the drug’s effectiveness using magnetic resonance imaging (MRI) indices. MRI is a non-invasive technique which allows doctors to monitor the effects of drug therapy on the brain lesions of MS patients.
Approximately 80 patients with relapsing remitting MS (the most common presenting form of the disease) will be enrolled into the study. They will receive either ATL1102 or placebo over eight weeks. ATL1102 will be delivered by subcutaneous injection on a twice weekly dosing schedule at a dose of 400mg per week. MRIs will be conducted at monthly intervals over the 8 week dosing period and at monthly intervals during the 8 week period following completion of dosing.
The principal investigator of the Phase IIa trial, Professor Volker Limmroth from the University of Essen in Germany is an internationally recognised clinical expert and researcher in the field of MS.
“ATL1102 represents a novel therapeutic approach to the treatment of MS and I am delighted to be associated with clinical trials using a technology that aims to stop the production of the disease causing protein, rather than deal with it after it is produced in the body”, said Professor Limmroth.
Recruitment of patients for the trial is underway and the company expects that the treatment and patient monitoring stages of the trial will be complete by early 2006, assuming patient recruitment proceeds at the anticipated rate, with results due to be reported mid 2006. |
Category: Development |
Clinical Areas: Neurology |
|
| - Return to the Previous Page - |
|
|
|
| |
|
KE Subscription:
